82772-93-8

Upstream product

• 4885-02-3 Dichloromethyl methyl ether 
• 33719-74-3 3,5-dichloroanisole 
• 86111-47-9 (2,6-dichloro-4-methoxy-phenyl)-methanol 
• 60964-09-2 2,6-dichloro-4-hydroxybenzaldehyde 
• 74-88-4 methyl iodide 
• 216257-25-9 3-chloro-5-[(triisopropylsilyl)oxy]phenyl chloride 
• 126663-61-4 1-<(tert-butyldimethylsilyl)oxy>-3,5-dichlorobenzene 
• 591-35-5 3,5-dichlorophenol 
• 59606-87-0 1,3-dichloro-2-(chloromethyl)-5-methoxybenzene 
• 50-00-0 formaldehyd 

Downstream Products

• 128412-96-4 1-(2,6-dichloro-4-methoxyphenyl)-2-(2-fluoro-4-methoxyphenyl)ethene 
• 128412-97-5 (E/Z)-1-(2-chloro-4-methoxyphenyl)-2-(2,6-dichloro-4-methoxyphenyl)ethene 
• 111086-59-0 d,l-1,2-bis-(2,6-dichlori-4-methoxyphenyl)ethylenediamine 
• 157487-25-7 trans-1,3-bis-(2,6-dichloro-4-methoxyphenyl)-2-propen-1-one 
• 157487-23-5 1-(2,6-dichloro-4-methoxyphenyl)ethan-1-ol 
• 128412-92-0 1,3-Dichloro-5-methoxy-2-((E)-styryl)-benzene 
• 128412-93-1 1,3-Dichloro-2-[(E)-2-(4-fluoro-phenyl)-vinyl]-5-methoxy-benzene 
• 128444-72-4 1,3-Dichloro-5-methoxy-2-[(E)-2-(4-methoxy-phenyl)-vinyl]-benzene 
• 128444-71-3 1-(2,6-dichloro-4-methoxyphenyl)-2-(3-methoxyphenyl)ethene 
• 128412-94-2 1,3-Dichloro-2-[(E)-2-(2,6-difluoro-phenyl)-vinyl]-5-methoxy-benzene 
• 128412-95-3 1,3-Dichloro-2-[(E)-2-(2,6-dichloro-phenyl)-vinyl]-5-methoxy-benzene 
• 354138-94-6 1,3-Dichloro-5-methoxy-2-[(Z)-2-(3-methoxy-phenyl)-vinyl]-benzene 
• 354138-83-3 1,3-Dichloro-5-methoxy-2-[(E)-2-(3-methoxy-phenyl)-vinyl]-benzene 
• 461031-79-8 4-(benzyloxy)-2,6-dichlorobenzaldehyde 

Relevant academic research and scientific papers

2-(2-ACRYLOYL-2,6-DIAZASPIRO[3.4]OCTAN-6-YL)-6-(1H-INDAZOL-4-YL)-BENZONITRILE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF G12C MUTANT KRAS PROTEIN FOR INHIBITING TUMOR METASTASIS

The present invention provides e.g. 2-(2-acryloyl-2,6- diazaspiro[3.4]octan-6-yl)-6-(lH-indazol-4-yl)-benzonitrile and e.g. 2-(2-acryloyl-2,7-diazaspiro[3.5]nonan-7-yl)-6-(1H-indazol-4-yl)- benzonitrile derivatives and related compounds of formula (I) as inhibitors of G12C mutant KRAS protein for treating tumor metastasis. The present description discloses exemplary compounds (e.g. pages 53 to 90; table 1; compounds I-1 to I-141), pharmacological data (e.g. page 125 to 128; table 2; example 1) and synthesis thereof (e.g. pages 129 to 143; examples 2 to 7). Exemplary compounds are e.g. 2-(2-acryloyl-2,6- diazaspiro[3.4]octan-6-yl)-6-(5-methyl-1H-indazol-4-yl)-4- morpholinobenzonitrile (example 2; compound I-1) and 6-(2- acryloyl-2,7-diazaspiro[3.5]nonan-7-yl)-3-methoxy-2-(5-methyl-1H- indazol-4-yl)-4-morpholinobenzonitrile (example 7; compound I-84).

CYCLOHEXYLPYRAZOLE-LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1

The present invention discloses novel compounds of Formula (I): having 11β-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compound

Synthesis of novel structurally simplified estrogen analogues with electron-donating groups in ring A

A library of 25 novel estrogen analogues were prepared in five to eight steps from mostly commercially available substituted anisoles via bromination, formylation, Corey-Fuchs reaction, elimination, and Sonogashira reaction. Georg Thieme Verlag Stuttgart.

TETRACYCLIC INHIBITORS OF JANUS KINASES

The present invention provides compounds that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.

CYCLOHEXYL SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1

The present invention discloses novel compounds of Formula I: having 11β -HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11β-HSD type 1 activity.

CYCLOHEXYLIMIDAZOLE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1

The present invention discloses novel compounds of Formula I: ( I ) having 11β-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds

INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1

The present invention discloses novel compounds of Formula I: (I) having 11 -HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11 -HSD type 1 activity.

INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1

The present invention discloses novel compounds of Formula I: ( I ) possessing 11β-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, cognitive disorders, and other conditions associated with 11β-HSD type 1 activity.

SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1

The present invention discloses novel compounds of Formula I: ( I ) possessing 11β -HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, cognitive disorders, and other conditions associated with 11 β -HSD type 1 activity.

PIERIDINYL SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1

ABSTRACT The present invention discloses novel compounds of Formula I: ( I ) having 11-Beta-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11-Beta-HSD type 1 activity. X-17433 PCT -1-